These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19539384)

  • 1. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure.
    Tousoulis D; Andreou I; Tentolouris C; Antoniades C; Papageorgiou N; Gounari P; Kotrogiannis I; Miliou A; Charakida M; Trikas A; Stefanadis C
    Int J Cardiol; 2010 Dec; 145(3):438-43. PubMed ID: 19539384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
    Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
    J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study.
    Ashton E; Windebank E; Skiba M; Reid C; Schneider H; Rosenfeldt F; Tonkin A; Krum H
    Int J Cardiol; 2011 Feb; 146(3):404-7. PubMed ID: 20085851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.
    Kjekshus J; Dunselman P; Blideskog M; Eskilson C; Hjalmarson A; McMurray JV; Waagstein F; Wedel H; Wessman P; Wikstrand J;
    Eur J Heart Fail; 2005 Oct; 7(6):1059-69. PubMed ID: 16227145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2, -9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice.
    Zhai X; Chi J; Tang W; Ji Z; Zhao F; Jiang C; Lv H; Guo H
    J Pharmacol Sci; 2014; 125(2):132-41. PubMed ID: 24859779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
    Andreou I; Tousoulis D; Miliou A; Tentolouris C; Zisimos K; Gounari P; Siasos G; Papageorgiou N; Papadimitriou CA; Dimopoulos MA; Stefanadis C
    Atherosclerosis; 2010 May; 210(1):194-8. PubMed ID: 19962701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.
    Montagnana M; Volpe A; Lippi G; Caramaschi P; Salvagno GL; Biasi D; Bambara LM; Guidi GC
    Clin Biochem; 2007 Aug; 40(12):837-42. PubMed ID: 17493602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of matrix metalloproteinases and inhibitors on the scleral tissue of lamina cribrosa in rat with experimental chronic ocular hypertension].
    Xu SL; Gao ZZ; Wang Y; Chen J
    Zhonghua Yan Ke Za Zhi; 2009 Mar; 45(3):260-5. PubMed ID: 19575923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes.
    He S; Prasanna G; Yorio T
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3737-45. PubMed ID: 17652746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
    Ichihara S; Noda A; Nagata K; Obata K; Xu J; Ichihara G; Oikawa S; Kawanishi S; Yamada Y; Yokota M
    Cardiovasc Res; 2006 Feb; 69(3):726-35. PubMed ID: 16165109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
    Brehmer B; Biesterfeld S; Jakse G
    Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
    Ergul A; Portik-Dobos V; Hutchinson J; Franco J; Anstadt MP
    Am J Hypertens; 2004 Sep; 17(9):775-82. PubMed ID: 15363819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure.
    Zacà V; Rastogi S; Imai M; Wang M; Sharov VG; Jiang A; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2007 Aug; 50(6):551-7. PubMed ID: 17678740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy.
    Lorenzl S; Albers DS; Chirichigno JW; Augood SJ; Beal MF
    J Neurol Sci; 2004 Mar; 218(1-2):39-45. PubMed ID: 14759631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of once weekly rosuvastatin among patients with a prior statin intolerance.
    Backes JM; Moriarty PM; Ruisinger JF; Gibson CA
    Am J Cardiol; 2007 Aug; 100(3):554-5. PubMed ID: 17659946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
    Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
    Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosuvastatin on fatigue in patients with heart failure.
    Perez AC; Jhund P; Preiss D; Kjekshus J; McMurray JJ
    J Am Coll Cardiol; 2013 Mar; 61(10):1121-2. PubMed ID: 23473415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.